Behavior of the combined use of plasma and Heberprot-P in diabetic ulcers, Guantánamo
DOI:
https://doi.org/10.62486/sic2025266Keywords:
Heberprot P, ulcer, diabetic foot, plasma, healingAbstract
Introduction: Diabetes Mellitus is one of the most common diseases. One of its most common complications is diabetic foot; this, in conjunction with other vascular alterations, can lead to amputation. The combined use of Heberprot-P and platelet-rich plasma provides another therapeutic alternative to facilitate healing.
Objective: To determine the behavior of the combined use of platelet-rich plasma and Heberprot-P in diabetic ulcers in the Angiology Department of the "Dr. Agoustinho Neto" General Teaching Hospital, 2025.
Method: A descriptive, retrospective, and longitudinal study was conducted. The sample consisted of (n = 50) patients discharged from the angiology department. Twenty-five patients with neuroinfectious diabetic foot and 25 with ischemic diabetic foot were randomly selected. The variables studied were: healing time, diabetic foot types, healing percentage, and Wagner grade.
Results: 70% of patients achieved 75% ulcer healing, of which 42% were neuroinfectious diabetic foot ulcers. The most common Wagner grade was grade II, at 48%. Fifty-four percent of patients achieved maximum healing between days 8 and 14. No significant changes occurred during the first week after starting treatment.
Conclusions: Neuroinfectious diabetic foot ulcers respond better to treatment with Heberprot P and Plasma. Wagner type II ulcers have a more satisfactory outcome than other ulcers. The use of these treatments reduces healing time by 2 weeks.
References
Berlanga J, Savigne W, Valdés C, Franco N, Alba JS, del Rio A, et al. Epidermal growth factor intra-lesional iniltrations can prevent amputation in diabetic patients with advanced foot ulcers. It Wound J. 2006; 3:232-9. DOI: https://doi.org/10.1111/j.1742-481X.2006.00237.x
Fernández ND,Calderón MR, Burgoa DD. Beneficios del plasma rico en plaquetas en el tratamiento de las úlceras crónicas por pie diabético. Rev Méd La Paz [Internet]. 2023 [citado 14 Feb 2024]; 29(2): [aprox. 7p]. Disponible en: https://www.scielo.org.bo/scielo.php?script=sci_arttext&pid=S1726-89582023000200086&lng=es.
Chícharo D, Rubio M, Damiá E, Carrillo J, Cuervo B y Peláez P. Platelet Rich Plasma: New Insights for Cutaneous Wound Healing Management. J Funct Biomater. 2018. 9: 1-20. DOI: https://doi.org/10.3390/jfb9010010
Izzo P, De Intinis C, Molle M, Polistena A, Sibio S, Codacci M, et al. Case report: The use of PRP in the treatment of diabetic foot: case series and a review of the literature. Front Endocrinol. 2023;14(2):86907.
Magalon J, Chateau A, Bertrand B, Louis M, Silvestre A, Giraudo L et al. DEPA classification: a proposal for standardizing PRP use and a retrospective application of available devices. BMJ Open Sport Exerc Med. 2016. 2: 1-5. DOI: https://doi.org/10.1136/bmjsem-2015-000060
Badran K y Sand J. Platelet-Rich Plasma for Hair Loss Review of Methods and Results. Facial Plast Surg Clin North Am. 2018. 26: 469-485. DOI: https://doi.org/10.1016/j.fsc.2018.06.008
Malekpour N, Shafiee A, Mirmohseni A, Besharat S. Evaluation of the efficacy of plateletrich plasma on healing of clean diabetic foot ulcers: A randomized clinical trial in Tehran, Iran. Diabetes Metab Syndr. 2021;15(2):621-6 DOI: https://doi.org/10.1016/j.dsx.2021.03.005
Jaseem M, Alungal S, Dhiyaneswaran H, Shamsudeen J. Effectiveness of autologous PRP therapy in chronic nonhealing ulcer: A 2-year retrospective descriptive study. J Family Med Prim Care. 2020;9(6):2818-22. DOI: https://doi.org/10.4103/jfmpc.jfmpc_177_20
OuYang H, Tang Y, Yang F, Ren X, Yang J, Cao H, et al. Platelet-rich plasma for the treatment of diabetic foot ulcer: a systematic review. Front Endocrinol. 2023;14(2):56081. DOI: https://doi.org/10.3389/fendo.2023.1256081
Izzo P, De Intinis C, Molle M, Polistena A, Sibio S, Codacci M, et al. Case report: The use of PRP in the treatment of diabetic foot: case series and a review of the literature. Front Endocrinol. 2023;14(2):86907 DOI: https://doi.org/10.3389/fendo.2023.1286907
Platini H, Amartya K, Maulana S, Moradha P, Layud W, Jeremis JA, et al. The Potential of Autologous Platelet-Rich Plasma Gel for Diabetic Foot Ulcer Care Among Older Adults: A Systematic Review and Meta-Analysis. Ther Clin Risk Manag. 2024;20(2):21-37. DOI: https://doi.org/10.2147/TCRM.S433033
González Consuegra JA, Roche Toledo JD. Evolución clínica y calidad de vida de pacientes con úlcera del pie diabético tratados con Heberprot-P®. Mediciego [Internet]. 17 de junio de 2024 [citado 21 de junio de 2025]; 30:e3911. Disponible en: https://revmediciego.sld.cu/index.php/mediciego/article/view/391
Published
Issue
Section
License
Copyright (c) 2025 Leonardo Basilé Romero, Pablo Javier Alcolea, Susana Esther Vargas Garcell, Leonardo Antonio Salgado Delgado (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
